VC Deals
Deciphera Pharmaceuticals, a Waltham, Mass.-based developer of kinase inhibitor treatments targeting tumors cells, has raised $75 million in Series B funding led by New Leaf Venture Partners
Portea Medica, an Indian home healthcare company, has raised $37.5 million in Series B funding. Accel Partners led the round, and was joined by the International Finance Corp., Qualcomm Ventures and Ventureast
Headspace, a Venice, Calif.-based maker of a meditation app, has raised $34 million in VC funding.The Chernin Group led the round, and was joined by Advancit Capital, Allen & Co., Breyer Capital, Broadway Video Ventures, Deerfield Management, Freelands Ventures, William Morris Endeavor and individual angels like Jeff Weiner, Jessica Alba, Jared Leto and Ryan Seacrest
Modernizing Medicine Inc., a Boca Raton, Fla.-based provider of cloud-based specialty-specific electronic medical record systems, has raised $38 million in Series E funding. Backers include Pentland Group, Summit Partners and Sands Venture Capital
Veran Medical Technologies Inc., a St. Louis-based developer of image-guided endobronchial and percutaneous technology for diagnosis of lung cancer and therapy delivery, has raised $30.6 million in new VC funding. Versant Ventures and River Cities Capital Fundsco-led the round, and were joined by return backers Prolog Ventures, Advantage Capital, Rex Health Ventures, 3G Capital, Dynamic Investments and Vectis
Prevtec Microbia, a Montreal-based developer of biological products for the prevention of diseases in food animals, has raised C$7.2 million in new equity funding. Backers include Investissement Quebec (C$2.5m), PIH Pharma Industry Holding GmbH, Telesystem Ltd., Groupe Jafaco Gestion Inc. and Desjardins-Innovatech
Whoop, a Boston-based performance optimization system for athletes and teams, has raised $12 million in Series B funding. Two Sigma Partners led the round, and was joined by Mousse Partners, Accomplice, Promus Ventures, Valley Oak Investments, and NextView Ventures
Skillz, a San Francisco-based mobile e-sports startup, has raised $15 million in Series B funding. David Bonderman’s Wildcat Capital Management led the round, and was joined by The Kraft Group, Sequoia Capital and Marc Lasry
Joylux Inc., a Seattle-based developer of therapeutic LED products for home use, has raised $3 million in seed funding from undisclosed investors
Auris Surgical Robotics, a San Carlos, Calif.-based developer of robotics technology for medical applications, has raised $150 million in new equity funding, according to a regulatory filing. A source close to the deal says it was led by a large public-market investor at a post-money valuation north of $600 million. Return backers include Lux Capital, Mithril Capital Management and Highland Capital Partners
Replimune, a UK-based developer of ‘oncolytic immunotherapies’ for cancer treatment, has raised $30 million in Series A funding. Atlas Venture led the round, and was joined by seed backers Forbion Capital Partners and Omega Funds
Just Biotherapeutics, a 1.5-year-old Seattle-based integrated design company focused on the technology of biotherapeutics, from molecule to manufacturing plant, has raised $15 million in Series A financing from Merck,Lilly Asia Ventures, and ARCH Venture Partners
Phasiq, a three-year-old, Ann Arbor, Michigan-based healthcare company whose technology helps scientists to measure protein levels in a multiplex and cross-reaction free manner, has raised an undisclosed amount of funding from backers that include The Zell Lurie Commercialization Fund, in collaboration with the Samuel Zell & Robert H. Lurie Institute for Entrepreneurial Studies at the University of Michigan
CliniCloud, a year-old, San Francisco-based company that makes connected medical devices for the home, has raised $5 million in seed funding, including from Tencent Holdings and Ping An Ventures
Metabiota, a seven-year-old, San Francisco-based company that uses a network of on-the-ground epidemiologists and risk analytics to track disease outbreaks, has raised $1 million from Google Ventures as an add-on to a $30 million round the company announced in May that included investors Data Collective,Capricorn Health & Special Opportunities, Industry Ventures,RSTPand WP Global Partners
Veran Medical Technologies, a 16-year-old, St. Louis, Mo.-based company that’s commercializing technologies to detect lung cancer at an early stage, has raised $30.6 million co-led by River Cities Capital Funds and Versant Ventures, with participation from earlier backers 3G Capital, Advantage Capital, Dynamic Investments, Rex Health Ventures, Prolog Ventures and Vectis
PE Deals
BioClinica Inc., a Newtown, Penn.-based provider of clinical trials services, has acquired Synowledge, a Miami, Fla.-based provider of drug safety, regulatory affairs and related IT services to the life sciences market. No financial terms were disclosed. BioClinica shareholders include Ampersand Capital Partners, JLL Partners and Water Street Healthcare Partners. Harris Williams & Co. managed the sale process
HealthPort-IOD, an Alpharetta, Gla.-based portfolio company of New Mountain Capital, has acquired ECS, a Phoenix-based provider of on-demand access to medical records and related services. No financial terms were disclosed
The Blackstone Group has expressed interest in acquiring BioMed Realty Trust Inc. (NYSE: BMR), a San Diego-based commercial landlord focused on biotech companies, according to Bloomberg. BioMed’s stock jumped on the news, and now has a market cap north of $4.3 billion
Thomas H. Lee Partners has acquired a majority stake in Healthcare Staffing Services, a Greenwood Village, Colo.-based provider of healthcare staffing services, from Altaris Capital Partners. No financial terms of the recap were disclosed
IPO Deals
Surgery Partners Inc., a Nashville, Tenn.-based surgical facilities operator backed by H.I.G. Capital, has set its IPO terms to nearly 14.29 million shares being offered at between $23 and $26 per share. It would have an initial market cap of around $1.18 billion, were it to price in the middle of its range. The company to trade on the Nasdaq under ticker symbol SGRY, with BofA Merrill Lynch, Goldman Sachs and Jefferies serving as lead underwriters. Surgery Partners reports $23 million of net income on $457 million in revenue for the first six months of 2015, compared to $9 million of net income on $147 million in revenue for the year-earlier period
Edge Therapeutics, a Berkeley Heights, N.J.-based developer of therapies for life-threatening neurological conditions, has set its IPO terms to nearly 5.67 million shares being offered at between $14 and $16 per share. It would have an initial market cap of around $388 million, were it to price in the middle of its range. The pre-revenue company plans to trade on the Nasdaq under ticker symbol EDGE, with Leerink Partners and Credit Suisse serving as co-lead underwriters. It has raised just over $100 million in VC funding, from firms like Sofinnova Ventures (9.2% pre-IPO stake), Venrock (8%), Janus Capital Management (8%), New Leaf Venture Partners (6.4%), Franklin Templeton (6.4%) and BioMed Ventures
Strongbridge Biopharma PLC, a Trevose, Penn.-based drug company focused on rare diseases like endogenous Cushing’s syndrome, has set its IPO terms to 4.25 million shares. This could raise around million, based on the $17.93 trading price of its shares last Friday on the Norwegian Over-The-Counter System. It plans to list on the Nasdaq under ticker symbol SBBP, with BofA Merrill Lynch and Stifel serving as lead underwriters. Shareholders in the pre-revenue company include TVM (12.6% pre-IPO stake), HealthCap (11.9%), RA Capital (10.9%) and New Enterprise Associates (8.5%)
Aclaris Therapeutics Inc., a Malvern, Penn.-based developer of dermatological therapeutics, has set its IPO terms to 5 million shares being offered at between $14 and $16 per share. It would have an initial market cap of around $291 million, were it to price in the middle of its range. The pre-revenue company plans to trade on the Nasdaq under ticker symbol ACRS, with Jefferies and Citigroup serving as lead underwriters. Aclaris has raised $31.5 million in VC funding from Vivo Ventures (31.2% pre-IPO stake), Fidelity Biosciences (28.5%) and Sofinova Ventures (12%)
Other Deals
Clinigen Group (AIM: CLIN) has agreed to acquireLink Healthcare, a specialty pharma company focused on Asia, Africa and Australasia, for upwards of £100 million
Intarcia Therapeutics, the “unicorn” biotech company initially focused on diabetes, has made its first-ever acquisition. The target was Phoundry Pharmaceuticals Inc., a North Carolina-based developer of more than 20 optimized peptides for treating metabolic diseases. Phoundry originally was a research unit within GlaxoSmithKline, which recently spun out and raised a bit of seed funding just last month from Pappas Ventures
Sources: Term Sheet, Financial Times, StrictlyVC, TechinAsia, CrunchBase, TechCrunch, Bloomberg
#healthtech #asia